Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D01502)
Name
Triclabendazole
Synonyms    Click to Show/Hide the Synonyms of This API
Triclabendazole; 68786-66-3; Fasinex; 6-Chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzo[d]imidazole; UNII-4784C8E03O; 6-chloro-5-(2,3-dichlorophenoxy)-2-methylsulfanyl-1H-benzimidazole; NVP-EGA230; CPD000466357; EGA230B; MLS001424101; CHEMBL1086440; 4784C8E03O; NCGC00164610-01; Triclabendazole, 98%; Triclabendazol; SMR000466357; 5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)benzimidazole; 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole; Egaten; Triclabendazolum; 5-[2,3-bis(chloranyl)phenoxy]-6-chloranyl-2-methylsulfanyl-1H-benzimidazole; Triclabendazol [INN-Spanish]; Triclabendazolum [INN-Latin]; CCRIS 8988; CGA 89317; 5-chloro-6-(2,3-dichlorophenoxy)-2-methylsulfanyl-1H-benzimidazole; 6-Chloro-5-(2,3-dichlorophenoxy)-2-methylthio-benzimidazole; Fasinex (TN); CGA-89317; Egaten (TN); 1H-BENZIMIDAZOLE, 5-CHLORO-6-(2,3-DICHLOROPHENOXY)-2-(METHYLTHIO)-; DSSTox_CID_23952; DSSTox_RID_80094; DSSTox_GSID_43952; Oprea1_236106; Triclabendazole (USAN/INN); cid_50248; MLS000759473; MLS000876812; SCHEMBL165712; BEN631; DTXSID7043952; BDBM58491; CHEBI:94759; Triclabendazole [USAN:INN:BAN]; HMS2051E16; HMS2232D14; HMS3370H02; HMS3393E16; HMS3652M16; HMS3715P16; HMS3744I09; KUC103451N; Pharmakon1600-01505786; HY-B0621; ZINC1444556; Tox21_112231; 1H-Benzimidazole, 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-; ANW-42745; MFCD00864519; NSC759250; s4114; STK332284; AKOS005439340; AKOS015950804; AC-7627; CCG-100881; CCG-268150; DB12245; KS-5329; MCULE-8131756770; MP-0274; NC00131; NSC-759250; SB17173; NCGC00164610-02; AK-68238; I018; SBI-0207022.P001; AB0013427; CAS-68786-66-3; FT-0602564; SW197511-2; Triclabendazole 100 microg/mL in Acetonitrile; D07364; AB00639964-10; AB00639964_12; AB00639964_13; 786T663; A836250; Q419739; SR-01000759363; SR-01000759363-4; Triclabendazole, VETRANAL(TM), analytical standard; BRD-K81916719-001-05-5; 6-Chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)benzimidazole; Triclabendazole, EuropePharmacopoeia (EP) Reference Standard; 5-Chloro-6-(2',3'-dichlorophenoxy)-2-(methylthio)benzimidazole; 5-chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzo[d]imidazole; 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylsulfanyl)-1H-1,3-benzodiazole; 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylsulfanyl)-1H-benzimidazole; Triclabendazole for system suitability, EuropePharmacopoeia (EP) Reference Standard
Clinical Status
Approved
PubChem CID
50248
Formula
C14H9Cl3N2OS
Canonical SMILES
CSC1=NC2=CC(=C(C=C2N1)Cl)OC3=C(C(=CC=C3)Cl)Cl
InChI
1S/C14H9Cl3N2OS/c1-21-14-18-9-5-8(16)12(6-10(9)19-14)20-11-4-2-3-7(15)13(11)17/h2-6H,1H3,(H,18,19)
InChIKey
NQPDXQQQCQDHHW-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=50248"></iframe>
3D MOL is unavailable 2D MOL
Physicochemical Properties Molecular Weight 359.7 Topological Polar Surface Area 63.2
XlogP 5.7 Complexity 365
Heavy Atom Count 21 Rotatable Bond Count 3
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 3
Full List of Drug Formulations (DFMs) Containing This API
          Triclabendazole 250 mg tablet Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Colloidal Silicon Dioxide; Iron Oxide Red; Lactose Monohydrate; Maize Starch; Magnesium Stearate; Methylhydroxyethylcellulose
                   Dosage Form Tablet
                   Company Novartis Pharmaceuticals Corporation
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [1]
Pregelatinized starch DIG Info Multidrug resistance protein 1 (Protein expression downregulation) [1]
References
1 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.